ATE403656T1 - Xanthinderivate als a2b- adenosinrezeptorantagonisten - Google Patents
Xanthinderivate als a2b- adenosinrezeptorantagonistenInfo
- Publication number
- ATE403656T1 ATE403656T1 AT03817096T AT03817096T ATE403656T1 AT E403656 T1 ATE403656 T1 AT E403656T1 AT 03817096 T AT03817096 T AT 03817096T AT 03817096 T AT03817096 T AT 03817096T AT E403656 T1 ATE403656 T1 AT E403656T1
- Authority
- AT
- Austria
- Prior art keywords
- receptor antagonists
- adenosine receptor
- xanthine derivatives
- xanthine
- derivatives
- Prior art date
Links
- 101150078577 Adora2b gene Proteins 0.000 title abstract 2
- 229940121359 adenosine receptor antagonist Drugs 0.000 title abstract 2
- 239000000296 purinergic P1 receptor antagonist Substances 0.000 title abstract 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 title 1
- 229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 title 1
- 206010012735 Diarrhoea Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2003/014085 WO2004106337A1 (en) | 2003-05-06 | 2003-05-06 | Xanthine derivatives as a2b adenosine receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE403656T1 true ATE403656T1 (de) | 2008-08-15 |
Family
ID=33488737
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03817096T ATE403656T1 (de) | 2003-05-06 | 2003-05-06 | Xanthinderivate als a2b- adenosinrezeptorantagonisten |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1622908B1 (de) |
| JP (1) | JP2006515316A (de) |
| CN (1) | CN100590125C (de) |
| AT (1) | ATE403656T1 (de) |
| AU (1) | AU2003249604B2 (de) |
| CA (1) | CA2524778C (de) |
| CY (1) | CY1108457T1 (de) |
| DE (1) | DE60322748D1 (de) |
| DK (1) | DK1622908T3 (de) |
| ES (1) | ES2311759T3 (de) |
| MX (1) | MXPA05011860A (de) |
| NZ (1) | NZ543416A (de) |
| PT (1) | PT1622908E (de) |
| SI (1) | SI1622908T1 (de) |
| WO (1) | WO2004106337A1 (de) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101198608B (zh) * | 2005-06-16 | 2011-04-27 | 吉利德帕洛阿尔托股份有限公司 | A2b腺苷受体拮抗剂的前药 |
| ES2270715B1 (es) | 2005-07-29 | 2008-04-01 | Laboratorios Almirall S.A. | Nuevos derivados de pirazina. |
| ES2274712B1 (es) | 2005-10-06 | 2008-03-01 | Laboratorios Almirall S.A. | Nuevos derivados imidazopiridina. |
| JP2009528389A (ja) * | 2006-03-02 | 2009-08-06 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ａアデノシン受容体拮抗剤 |
| WO2009088518A1 (en) * | 2008-01-11 | 2009-07-16 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for the treatment of cancer |
| US8871751B2 (en) | 2008-01-18 | 2014-10-28 | The Board Of Trustees Of The University Of Illinois | Compositions and methods relating to nuclear hormone and steroid hormone receptors including inhibitors of estrogen receptor alpha-mediated gene expression and inhibition of breast cancer |
| EP2268641B1 (de) | 2008-03-26 | 2014-09-03 | Advinus Therapeutics Pvt. Ltd. | Heterocyclische verbindungen als adenosinrezeptorantagonist |
| WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
| JP5765239B2 (ja) | 2009-03-13 | 2015-08-19 | アドヴィナス・セラピューティックス・リミテッド | 置換縮合ピリミジン化合物 |
| US8796290B2 (en) | 2009-11-09 | 2014-08-05 | Advinus Therapeutics Limited | Substituted fused pyrimidine compounds, its preparation and uses thereof |
| AU2011303420B2 (en) * | 2010-09-13 | 2014-03-20 | Impetis Biosciences Ltd. | Purine compounds as prodrugs of A2B adenosine receptor antagonists, their process and medicinal applications |
| UA117470C2 (uk) | 2013-03-15 | 2018-08-10 | Гайдра Байосаєнсиз, Інк. | Заміщені ксантини та способи їх застосування |
| ES2580702B1 (es) | 2015-02-25 | 2017-06-08 | Palobiofarma, S.L. | Derivados de 2-aminopiridina como antagonistas del receptor A2b de adenosina y ligandos del receptor MT3 de melatonina |
| EP3389664A4 (de) * | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | Koffeininhibitoren von mthfd2 und verwendungen dafür |
| WO2018204661A1 (en) * | 2017-05-05 | 2018-11-08 | Arcus Biosciences, Inc. | Quinazoline-pyridine derivatives for the treatment of cancer-related disorders |
| WO2019173380A1 (en) * | 2018-03-05 | 2019-09-12 | Teon Therapeutics, Inc. | Adenosine receptor antagonists and uses thereof |
| CN113727999A (zh) | 2019-01-11 | 2021-11-30 | 奥默罗斯公司 | 用于治疗癌症的方法和组合物 |
| CN118459463B (zh) * | 2024-07-10 | 2024-09-06 | 山东中医药大学附属医院 | 一种化合物及其制备方法和治疗2型糖尿病的用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8510758D0 (en) * | 1985-04-27 | 1985-06-05 | Wellcome Found | Compounds |
| US4878296A (en) * | 1988-04-22 | 1989-11-07 | The United States Of America As Represented By The Secretary Of The Navy | Apparatus and method for locating the axis of symmetry (center of circular cross section) of three dimensional objects |
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| JPH06102662B2 (ja) * | 1989-09-01 | 1994-12-14 | 協和醗酵工業株式会社 | キサンチン誘導体 |
| WO1995011681A1 (en) * | 1993-10-29 | 1995-05-04 | Merck & Co., Inc. | Human adenosine receptor antagonists |
| DE19535504A1 (de) * | 1995-09-25 | 1997-03-27 | Bayer Ag | Substituierte Xanthine |
| US6117878A (en) * | 1998-02-24 | 2000-09-12 | University Of Virginia | 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors |
| ES2189079T3 (es) * | 1998-04-24 | 2003-07-01 | Leuven K U Res & Dev | Efectos inmunosupresores de derivados de xantina 8-sustituidos. |
| US6545002B1 (en) * | 1999-06-01 | 2003-04-08 | University Of Virginia Patent Foundation | Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors |
| JP4335000B2 (ja) * | 2001-06-29 | 2009-09-30 | シーブイ・セラピューティクス・インコーポレイテッド | Ａ２ｂアデノシン・レセプタ拮抗剤 |
| KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | Ａ２ｂ 아데노신 수용체 길항제 |
| CA2443023A1 (en) * | 2002-02-01 | 2003-08-07 | King Pharmaceuticals Research And Development, Inc. | 8-heteroaryl xanthine adenosine a2b receptor antagonists |
-
2003
- 2003-05-06 DE DE60322748T patent/DE60322748D1/de not_active Expired - Lifetime
- 2003-05-06 PT PT03817096T patent/PT1622908E/pt unknown
- 2003-05-06 AT AT03817096T patent/ATE403656T1/de active
- 2003-05-06 AU AU2003249604A patent/AU2003249604B2/en not_active Ceased
- 2003-05-06 JP JP2005500296A patent/JP2006515316A/ja active Pending
- 2003-05-06 DK DK03817096T patent/DK1622908T3/da active
- 2003-05-06 EP EP03817096A patent/EP1622908B1/de not_active Expired - Lifetime
- 2003-05-06 ES ES03817096T patent/ES2311759T3/es not_active Expired - Lifetime
- 2003-05-06 WO PCT/US2003/014085 patent/WO2004106337A1/en not_active Ceased
- 2003-05-06 MX MXPA05011860A patent/MXPA05011860A/es active IP Right Grant
- 2003-05-06 SI SI200331355T patent/SI1622908T1/sl unknown
- 2003-05-06 NZ NZ543416A patent/NZ543416A/en not_active IP Right Cessation
- 2003-05-06 CA CA2524778A patent/CA2524778C/en not_active Expired - Fee Related
- 2003-05-06 CN CN03826411A patent/CN100590125C/zh not_active Expired - Fee Related
-
2008
- 2008-10-27 CY CY20081101212T patent/CY1108457T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2524778C (en) | 2013-01-29 |
| CN1771250A (zh) | 2006-05-10 |
| WO2004106337A1 (en) | 2004-12-09 |
| AU2003249604A1 (en) | 2005-01-21 |
| JP2006515316A (ja) | 2006-05-25 |
| DE60322748D1 (de) | 2008-09-18 |
| CN100590125C (zh) | 2010-02-17 |
| EP1622908A1 (de) | 2006-02-08 |
| HK1092137A1 (en) | 2007-02-02 |
| CA2524778A1 (en) | 2004-12-09 |
| SI1622908T1 (sl) | 2008-12-31 |
| EP1622908B1 (de) | 2008-08-06 |
| ES2311759T3 (es) | 2009-02-16 |
| MXPA05011860A (es) | 2006-02-17 |
| DK1622908T3 (da) | 2008-11-17 |
| NZ543416A (en) | 2009-01-31 |
| CY1108457T1 (el) | 2014-04-09 |
| PT1622908E (pt) | 2008-11-14 |
| AU2003249604B2 (en) | 2011-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60322748D1 (de) | Xanthinderivate als a2b-adenosinrezeptorantagonisten | |
| ATE461932T1 (de) | Pyrazoloä4,3-eü-1,2,4-triazoloä1,5-cüpyrimidine als antagonisten des adenosin-a2a-rezeptors | |
| WO2003042214A3 (en) | A2b adenosine receptor antagonists | |
| CY2017015I2 (el) | ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS | |
| ATE387446T1 (de) | Pyrido(2,3-d)pyrimidin-2,4-diamine als pde-2- inhibitoren | |
| ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
| ATE513549T1 (de) | Ortho-kondensierte pyridin- und pyridimidin- derivate (z.b. purine) als proteinkinase-hemmer | |
| DE122012000043I1 (de) | Pyrrolo[2,3-B]pyridinderivate als proteinkinaseinhibitoren. | |
| DE60313872D1 (de) | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen | |
| ATE317844T1 (de) | Adenosine a2a receptor antagonisten | |
| IL183706A0 (en) | 2,4(4,6) pyrimidine derivatives | |
| DE60332396D1 (de) | PYRAZOLOi3,4-B PYRIDINVERBINDUNGEN UND IHRE VERWENDUNG ALS PHOSPHODIESTERASE INHIBITOREN | |
| MXPA03008967A (es) | Antagonistas receptores de 8-heteroarilo xantina adenosina a-2b. | |
| ATE360632T1 (de) | Substituierte 8'-pyri(mi)dinyl-dihydrospiro- (cycloalkylamin)-pyrimido(1,2a)pyrimidin-6- onderivate | |
| DE602006007556D1 (de) | Heteroarylsulfonylstilbene als 5-ht2a-antagonisten | |
| ATE422198T1 (de) | Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten | |
| ATE452892T1 (de) | Substituierte 8-perfluoro-6,7,8,9- tetrahydropyrimido-(1,2a) pyrimidin-4-on derivate | |
| DE602004018637D1 (de) | A2a-adenosinrezeptorantagonisten | |
| NO20080278L (no) | Prodrugs av A2B-adenosinreseptorantagonister | |
| DK1608653T3 (da) | Substituerede 8-perfluoroalkyl-6,7,8,9- tetrahydropyrimido (1,2-a) pyrimidin-4-on derivater | |
| DE60317684D1 (de) | SUBSTITUIERTE 2,4-DIHYDROPYRROLOc3,4BÜCHINOLIN-9-ONDERIVATE, DIE SICH ALS PHOSPHODIESTERASEINHIBITOREN EIGNEN | |
| ATE394402T1 (de) | Kondensierte purinderivate als a1- adenosinrezeptorantagonisten | |
| IS7507A (is) | Ný efnasambönd | |
| BRPI0512547A (pt) | pirimidinas | |
| ATE538123T1 (de) | 2-heteroarylpyrazoloä4,3-eü-1, 2, 4-triazolo-ä1,5-cü-pyrimidine als antagonisten des adenosin-a2a- rezeptors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1622908 Country of ref document: EP |